NASDAQ · INBX
Inhibrx Biosciences Inc.
$69.59-$4.06 (-5.51%)
Inhibrx Biosciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.19% below the high.
Loading market information…
NASDAQ · CATB · USD
Stock price
Quote as of Sep 9, 2021, 04:00 AM UTC. Cached market data; not a live quote.
Price history is currently unavailable.
Catabasis Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 7.27% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic treatments primarily within the United States. Their leading experimental drug, edasalonexent, is an oral small molecule undergoing Phase III clinical trials for Duchenne Muscular Dystrophy (DMD), functioning by inhibiting nuclear factor kappa-light-chain-enhancer of activated B cells. Additionally, the company is developing CAT-5571 as a potential treatment for cystic fibrosis. Catabasis also engages in collaborative research, including a preclinical partnership with the Jain Foundation to investigate edasalonexent for dysferlinopathy, and an agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 for both drug-sensitive and drug-resistant tuberculosis. The company was established in 2008 and is based in Boston, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:18 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
THE ANALYST VIEW
6 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$69.59-$4.06 (-5.51%)
Inhibrx Biosciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.19% below the high.
$4.00+$0.01 (+0.25%)
Inozyme Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 35.9% below the high.
$5.38-$0.01 (-0.09%)
Third Harmonic Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.42% below the high.
$2.27$0.00 (0.0%)
Acelyrin, Inc.’s quoted price sits in the lower half of its reported 52-week range, 68.69% below the high.
$3.17-$0.25 (-7.31%)
Cytocom, Inc.’s quoted price sits in the lower half of its reported 52-week range, 9.43% below the high.
$15.15+$0.02 (+0.1%)
Merrimack Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.69% below the high.
$4.47$0.00 (0.0%)
CARGO Therapeutics, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 82.44% below the high.
$1.03-$0.01 (-0.49%)
Spectrum Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 34.71% below the high.
